Literature DB >> 9370904

Enhanced drug metabolism in young children with cystic fibrosis.

A C Parker1, P Pritchard, T Preston, R L Smyth, I Choonara.   

Abstract

The effect of cystic fibrosis on caffeine metabolism was studied in young children using the caffeine breath test. Eight children with cystic fibrosis aged 2-6 years and nine age matched controls were studied on a single occasion, and the cumulative percentage of labelled caffeine exhaled as carbon dioxide measured over two hours. This was significantly higher in the patients with cystic fibrosis than in controls, suggesting an increase in the CYP1A2 metabolic pathway in the former. The fact that these were young children with minimal lung and liver disease suggests that enhanced drug metabolism in children with cystic fibrosis is hereditary rather than secondary to lung and liver damage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9370904      PMCID: PMC1717318          DOI: 10.1136/adc.77.3.239

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  17 in total

1.  Clinical diagnosis with the stable isotope 13C in CO2 breath tests: methodology and fundamental considerations.

Authors:  D A Schoeller; J F Schneider; N W Solomons; J B Watkins; P D Klein
Journal:  J Lab Clin Med       Date:  1977-09

2.  Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease.

Authors:  D C Knoppert; M Spino; R Beck; J J Thiessen; S M MacLeod
Journal:  Clin Pharmacol Ther       Date:  1988-09       Impact factor: 6.875

Review 3.  The CO2 breath tests as monitors of the cytochrome P450 dependent mixed function monooxygenase system.

Authors:  G H Lambert; A N Kotake; D Schoeller
Journal:  Prog Clin Biol Res       Date:  1983

4.  Hepatic drug clearance in patients with mild cystic fibrosis.

Authors:  G L Kearns; W R Crom; K H Karlson; G B Mallory; W E Evans
Journal:  Clin Pharmacol Ther       Date:  1996-05       Impact factor: 6.875

5.  Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects.

Authors:  J X Mazoit; P Sandouk; P Zetlaoui; J M Scherrmann
Journal:  Anesth Analg       Date:  1987-04       Impact factor: 5.108

6.  Rapid sample throughput for biomedical stable isotope tracer studies.

Authors:  T Preston; D C McMillan
Journal:  Biomed Environ Mass Spectrom       Date:  1988-10

7.  Effect of growth hormone therapy in growth hormone-deficient children on cytochrome P-450-dependent 3-N-demethylation of caffeine as measured by the caffeine 13CO2 breath test.

Authors:  L L Levitsky; D A Schoeller; G H Lambert; D V Edidin
Journal:  Dev Pharmacol Ther       Date:  1989

8.  Theophylline disposition in cystic fibrosis.

Authors:  A Isles; M Spino; E Tabachnik; H Levison; J Thiessen; S MacLeod
Journal:  Am Rev Respir Dis       Date:  1983-04

9.  Increased energy expenditure in young children with cystic fibrosis.

Authors:  R W Shepherd; T L Holt; L Vasques-Velasquez; W A Coward; A Prentice; A Lucas
Journal:  Lancet       Date:  1988-06-11       Impact factor: 79.321

10.  The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers.

Authors:  A N Kotake; D A Schoeller; G H Lambert; A L Baker; D D Schaffer; H Josephs
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

View more
  7 in total

Review 1.  Drug trials in children: problems and the way forward.

Authors:  S Conroy; J McIntyre; I Choonara; T Stephenson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 2.  Drug disposition in cystic fibrosis.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1998-10       Impact factor: 6.447

Review 3.  A systematic review of pharmacokinetics studies in children with protein-energy malnutrition.

Authors:  Kazeem A Oshikoya; Helen M Sammons; Imti Choonara
Journal:  Eur J Clin Pharmacol       Date:  2010-06-16       Impact factor: 2.953

4.  Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.

Authors:  J L Taylor-Cousar; C Wiley; L A Felton; C St Clair; M Jones; D Curran-Everett; K Poch; D P Nichols; G M Solomon; M T Saavedra; F J Accurso; J A Nick
Journal:  J Cyst Fibros       Date:  2014-11-13       Impact factor: 5.482

5.  Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice.

Authors:  Emily M Bradford; Maureen A Sartor; Lara R Gawenis; Lane L Clarke; Gary E Shull
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-22       Impact factor: 4.052

6.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10

7.  Effect of Casilan(®) on (13)C-caffeine metabolism in overnight-fasted healthy Nigerian children.

Authors:  Kazeem A Oshikoya; Ken Smith
Journal:  J Pharmacol Pharmacother       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.